| Mark H Lee, MD | |
|
2201 Chapel Ave W, Cherry Hill, NJ 08002-2048 | |
| (856) 488-6500 | |
| (856) 488-6507 |
| Full Name | Mark H Lee |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 2201 Chapel Ave W, Cherry Hill, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174729974 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| St Luke's Hospital - Monroe Campus | Stroudsburg, PA | Hospital |
| St Luke's Warren Hospital | Phillipsburg, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Progressive Physician Assoc Inc | 1355243809 | 118 |
| Progressive Physician Assoc Inc | 1355243809 | 118 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Entity Name | Radiology Associates Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659390870 PECOS PAC ID: 8820027634 Enrollment ID: O20050811000306 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Entity Name | The New Jersey Imaging Network, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629327887 PECOS PAC ID: 2860633492 Enrollment ID: O20130724000791 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Entity Name | Progressive Physician Assoc Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881646859 PECOS PAC ID: 1355243809 Enrollment ID: O20140312000133 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Entity Name | Jefferson University Physicians Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083039200 PECOS PAC ID: 9931325131 Enrollment ID: O20140724000727 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Entity Name | Garden State Radiology Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487056768 PECOS PAC ID: 3870815244 Enrollment ID: O20141215000979 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Entity Name | Lenox Hill Radiology & Medical Imaging Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821036807 PECOS PAC ID: 2264424712 Enrollment ID: O20180404000407 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark H Lee, MD 2201 Chapel Ave W, Cherry Hill, NJ 08002-2048 Ph: (856) 488-6500 | Mark H Lee, MD 2201 Chapel Ave W, Cherry Hill, NJ 08002-2048 Ph: (856) 488-6500 |
News Archive
A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.
Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
In a large population-based study of randomly selected participants in Germany, researchers found that mild cognitive impairment (MCI) occurred significantly more often in individuals diagnosed with a lower ankle brachial index (ABI), which is a marker of generalized atherosclerosis and thus cumulative exposure to cardiovascular risk factors during lifetime.
› Verified 1 days ago
Vishal Desai, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Chapel Ave W, Cherry Hill, NJ 08002 Phone: 856-488-6500 Fax: 856-488-6507 | |
Eyal Barzel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 207 Kings Hwy S, #2, Cherry Hill, NJ 08034 Phone: 856-616-8600 Fax: 856-616-8601 | |
Chia-en Hsu, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 2201 Chapel Ave W, Radiology Department, Cherry Hill, NJ 08002 Phone: 856-488-6844 Fax: 856-488-6507 | |
Evan Rochlis, MD Radiology Medicare: Medicare Enrolled Practice Location: 2201 Chapel Ave W, Cherry Hill, NJ 08002 Phone: 856-922-4360 | |
Igor G Rayevsky, MD Radiology Medicare: Medicare Enrolled Practice Location: 1112 Winding Dr, Cherry Hill, NJ 08003 Phone: 856-429-0300 Fax: 856-429-0300 | |
Carol L Kornmehl, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2090 Springdale Rd Ste B, Cherry Hill, NJ 08003 Phone: 856-751-9010 | |
John Alaric Lentini, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2201 Chapel Ave W, Cherry Hill, NJ 08002 Phone: 564-886-5008 Fax: 856-922-5109 |